EPFL Innovation Park, Lausanne
Envoyer mon évaluation

Portrait d'entreprise

Asceneuron is an emerging biotech company specializing in the discovery and development of groundbreaking small molecule therapeutics for neurodegenerative diseases


We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.

To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).


Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures.

Our executive management team combines research and development excellence with business and fundraising experience to bring innovation to patients. Our highly skilled scientists have extensive experience in all aspects of the drug discovery value chain. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.

Asceneuron pursues a semi-virtual operating model. Our unique biochemical assays, biomarker discovery activities and pharmacology models are pursued in-house, while we collaborate with leading contract research organizations for other activities such as medicinal chemistry. Asceneuron operates in a state-of-the-art facility at the EPFL Innovation Park in Lausanne, Switzerland, in proximity to leading academic institutions in the Lake Geneva area.

Our lead product, an O-GlcNAcase inhibitor which has been demonstrated to modulate tau pathology in preclinical studies, has entered human clinical testing in healthy volunteers. The O-GlcNAcase inhibitor is being developed for the orphan tauopathy Progressive Supranuclear Palsy (PSP).

Offres d'emploi

Il n'y a actuellement pas de postes vacants.

Gardez un œil sur cette entreprise en l'ajoutant à vos favoris.


Actuellement aucune évaluation
Partagez votre expérience avec les autres candidats et soyez le premier à évaluer cette entreprise.
EPFL Innovation Park


Biotechnologie / Chimie / Pharmaceutique

Année de création

Ce site web utilise des cookies afin d'offrir le meilleur service possible. Pour plus de détails, consultez nos Conditions générales et nos informations sur la Protection des données.